Relationship of Insulin Dose, A1c Lowering, and Weight in Type 2 Diabetes: Comparing Insulin Glargine and Insulin Detemir

Overview

Journal Diabetes Technol Ther

Specialties Endocrinology
Pharmacology

Date 2010 Dec 7

PMID 21128849

Citations 13

Authors

George Dailey

Karim Admane

Florence Mercier

David Owens

Affiliations

Soon will be listed here.

Abstract

Background: A pooled analysis of randomized controlled trials of individuals with type 2 diabetes mellitus (T2DM) was conducted to compare dosing and impact of two basal insulin analogs, insulin glargine (glargine) and insulin detemir (detemir), on weight and hemoglobin A1c (A1c).

Methods: Twenty-two studies of at least 20 weeks in duration in individuals with T2DM initiating glargine/detemir were included. Results were combined using a weighted-average method and a bivariate random effect model. Outcomes included changes in weight, A1c, and insulin dose from study start to end.

Results: One study was head-to-head comparison of glargine and detemir. Detemir (four studies) was administered once or twice daily, with 50% starting on detemir once daily but needing therapy intensification. Glargine was used once daily in all 22 studies. The Egger test was borderline significant for change in weight over the course of the treatment for glargine (0.29; 90% confidence interval [CI] -0.01, 0.58), and heterogeneity was not observed for detemir (-0.18; 90% CI -0.59, 0.23). Heterogeneity was observed for change in A1c over the course of the treatment (glargine, -1.19, 90% CI -1.74, -0.63; detemir, -2.65, 90% CI -4.86, -0.45). Nonheterogeneity for change in A1c over the course of the treatment was achieved by excluding five studies for glargine and one study for detemir; however, all studies were included in subsequent analyses. In the unadjusted model, glargine and detemir showed similar results for mean A1c change (-1.4% vs. -1.4%), weight gain (2.5 vs. 1.7 kg), and weight/A1c (1.8 vs. 1.2 kg/%). A significantly higher detemir dose was needed to achieve the same A1c change (51.5 vs. 38.8 U/day).

Conclusions: Although absolute weight gain was higher with glargine versus detemir, weight gain per A1c change was similar. A higher detemir dose was required to achieve a similar A1c reduction.

Citing Articles

IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study.

Malighetti M, Molteni L, Orsi E, Serra R, Gaglio A, Mazzoleni F Acta Diabetol. 2024; 62(3):367-374.

PMID: 39235480 PMC: 11872972. DOI: 10.1007/s00592-024-02361-7.

Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences.

Davidson M Clin Diabetes. 2023; 41(3):438-441.

PMID: 37456099 PMC: 10338278. DOI: 10.2337/cd22-0106.

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity.

Ge D, Foer D, Cahill K Pulm Ther. 2022; 9(1):71-89.

PMID: 36575356 PMC: 9931991. DOI: 10.1007/s41030-022-00211-x.

Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda-a descriptive retrospective study.

Tino S, Mayanja B, Mubiru M, Eling E, Ddumba E, Kaleebu P BMJ Open. 2020; 10(11):e039258.

PMID: 33148749 PMC: 7643505. DOI: 10.1136/bmjopen-2020-039258.

A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes.

Forst T, Choudhary P, Schneider D, Linetzky B, Pozzilli P Diabetes Metab Res Rev. 2020; 37(6):e3418.

PMID: 33098260 PMC: 8519070. DOI: 10.1002/dmrr.3418.

References

Bretzel R, Nuber U, Landgraf W, Owens D, Bradley C, Linn T . Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008; 371(9618):1073-84. DOI: 10.1016/S0140-6736(08)60485-7. View

Monnier L, Colette C . Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006; 12 Suppl 1:42-6. DOI: 10.4158/EP.12.S1.42. View

Rosenstock J, Sugimoto D, Strange P, Stewart J, Soltes-Rak E, Dailey G . Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006; 29(3):554-9. DOI: 10.2337/diacare.29.03.06.dc05-0695. View

Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract. 2006; 73(1):35-40. DOI: 10.1016/j.diabres.2005.12.009. View

Vague P, Selam J, Skeie S, De Leeuw I, Elte J, Haahr H . Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003; 26(3):590-6. DOI: 10.2337/diacare.26.3.590. View

Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K . Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006; 49(3):442-51. DOI: 10.1007/s00125-005-0132-0. View

Pieber T, Draeger E, Kristensen A, Grill V . Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005; 22(7):850-7. DOI: 10.1111/j.1464-5491.2005.01545.x. View

Hermansen K, Fontaine P, Kukolja K, Peterkova V, Leth G, Gall M . Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004; 47(4):622-9. DOI: 10.1007/s00125-004-1365-z. View

Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts V, Thorsteinsson B . Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006; 28(10):1569-81. DOI: 10.1016/j.clinthera.2006.10.020. View

10.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg J, Abrams P . Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004; 27(5):1081-7. DOI: 10.2337/diacare.27.5.1081. View

11.

Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005; 7(1):56-64. DOI: 10.1111/j.1463-1326.2004.00373.x. View

12.

Janka H, Plewe G, Riddle M, Kliebe-Frisch C, Schweitzer M, Yki-Jarvinen H . Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005; 28(2):254-9. DOI: 10.2337/diacare.28.2.254. View

13.

Davies M, Khunti K . Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Diabetes Obes Metab. 2008; 10 Suppl 2:42-9. DOI: 10.1111/j.1463-1326.2008.00844.x. View

14.

De Leeuw I, Vague P, Selam J, Skeie S, Lang H, Draeger E . Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005; 7(1):73-82. DOI: 10.1111/j.1463-1326.2004.00363.x. View

15.

Gerstein H, Yale J, Harris S, Issa M, Stewart J, Dempsey E . A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies.... Diabet Med. 2006; 23(7):736-42. DOI: 10.1111/j.1464-5491.2006.01881.x. View

16.

Korytkowski M . When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26 Suppl 3:S18-24. DOI: 10.1038/sj.ijo.0802173. View

17.

Russell-Jones D, Khan R . Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab. 2007; 9(6):799-812. DOI: 10.1111/j.1463-1326.2006.00686.x. View

18.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29(6):1269-74. DOI: 10.2337/dc05-1365. View

19.

Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M . Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications. 2006; 20(3):145-52. DOI: 10.1016/j.jdiacomp.2005.09.004. View

20.

Makimattila S, Nikkila K, Yki-Jarvinen H . Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 1999; 42(4):406-12. DOI: 10.1007/s001250051172. View